	US 12,144,823 B2
	Porous silicate and/or aluminosilicate matrix/cerium oxide nanoparticle nanocarrier for combination anti-cancer therapeutic and antioxidant delivery
B. Rabindran Jermy, Dammam (SA); Vijaya Ravinayagam, Dammam (SA); and Sarah Almofty, Dammam (SA)
Assigned to Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed by Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed on Apr. 28, 2022, as Appl. No. 17/731,905.
Prior Publication US 2023/0346833 A1, Nov. 2, 2023
Int. Cl. A61K 33/243 (2019.01); A61K 9/14 (2006.01); A61K 31/12 (2006.01); A61K 31/122 (2006.01); A61K 31/282 (2006.01); A61K 31/352 (2006.01); A61K 31/7048 (2006.01); A61K 47/02 (2006.01); A61P 35/00 (2006.01)

CPC A61K 33/243 (2019.01) [A61K 9/14 (2013.01); A61K 31/12 (2013.01); A61K 31/122 (2013.01); A61K 31/282 (2013.01); A61K 31/352 (2013.01); A61K 31/7048 (2013.01); A61K 47/02 (2013.01); A61P 35/00 (2018.01)]

18 Claims

1. A method for treating a cancer in a subject, comprising administering to a subject in need thereof a pharmaceutical composition comprising a nanomedicinal composition, comprising

a nanocarrier comprising:

a porous silicate and/or aluminosilicate matrix which is at least one selected from the group consisting of particles of mesoporous silica and halloysite nanotubes; and

cerium oxide nanoparticles having a mean particle size of 1 to 20 nm disposed on the porous silicate and/or aluminosilicate matrix; and

a pharmaceutical agent mixture comprising a platinum (II) complex and an antioxidant, the pharmaceutical agent mixture being disposed in the pores and/or on a surface of the nanocarrier, wherein

the nanocarrier has a surface area of 15 to 80 m²/g;

the nanocarrier is substantially free of silanes and organosilicates, and

the cancer is at least one selected from the group consisting of breast cancer, colorectal cancer, and lung cancer.